Cancer Screening

Preface; Part I. Screening for Breast Cancer: State of the Art on Breast Cancer Screening: 1. Sensitivity and specificity of screening in the UK trial of early detection of breast cancer; 2. Screening for breast cancer in Finland; 3. The Swedish two-county trial of mammographic screening for breast cancer: recent results on mortality and tumour characteristics; 4. The Malmoe mammographic screening trial; 5. The Canadian national breast screening study; 6. The USSR/Germany/WHO BSE study and global strategies for the control of breast cancer; 7. A cost-effectiveness approach to breast cancer screening; 8. Summary of the discussion on breast cancer screening; Part II. Screening for Colorectal Cancer: State of the Art on Screening for Colorectal Cancer: 9. Colon cancer control study: status and current issues; 10. An update on the Nottingham trial of faecal occult blood screening and rescreening of 51 325 subject; 12. Interim report on a randomised trial of screening for colorectal cancer with Hemoccult-II; 13. Case-control evaluation of colorectal cancer screening in the Federal Republic of Germany; 14. Summary of the discussion on colorectal cancer screening; Part III. Screening of Cancer for the Cervix: State of the Art on Screening for Cancer of the Cervix: 15. The natural history of cancer of the cervix, and the implications for screening policy; 16. Effect of organized screening on the risk of cervical cancer in the Nordic countries; 17. The organisation of cervical screening in England and Wales; 18. Indications for colposcopy from a UK viewpoint; 19. Screening for cervix cancer in developing countries; 20. Summary of the discussion on screening for cancer of the cervix; Part IV. Screening for Ovarian Cancer: State of the Art on Screening for Ovarian Cancer: 21. Tumour markers in screening for ovarian cancer; 22. Phase I investigation for early diagnosis of ovarian carcinoma; what problems are to be expected in a larger screening programme?; 23. Screening for ovarian cancer; 24. Summary of the discussion on screening for ovarian cancer; Part V. Screening for Malignant Melanoma: State of the Art on Screening for Melanoma: 25. Screening and early diagnosis for melanoma in Australia and New Zealand; 26. Screening for melanoma in the UK; 27. Screening for melanoma/skin cancer in the United States; 28. The dysplastic naevus syndrome: implications for screening; 29. Summary of the discussion on screening for melanoma of the skin; Part VI. Screening for Prostate Cancer: State of the Art on Screening for Prostate Cancer: 30. Issue in screening for prostate cancer; 31. Available screening tests for prostate cancer; 32. Evaluation of screening for prostate, lung and colorectal cancers :the PLC trial; 33. Summary of the discussion on screening for cancer of the prostate; Part VII. Screening for Neuroblastoma: State of the Art on Screening for Neuroblastoma: 34. Neuroblastoma: studies in Japan; 35. Screening for neuroblastoma, background, preliminary experience in the North of England and proposals for an evaluative study; 36. Summary of the discussion on screening for neuroblastoma; Part VIII. Screening for Stomach Cancer: State of the Art on Screening for Stomach Cancer: 37. Evaluation of mass screening programme for stomach cancer in Japan; 38. Summary for the discussion of screening for stomach cancer; Part IX. Screening for Nasopharyngeal Cancer: State of the Art on Screening for Nasopharyngeal Cancer: 39. Screening for nasopharyngeal carcinoma; 40. Summary of the discussion on screening for nasopharyngeal cancer; Part X. Methodological Issues: 41. Surrogate measures in the design of breast screening trials; 42. Recent developments in cancer screening modeling; 43. Case-control studies of screening; 44. Summary of the discussion on new approaches to the evaluation of screening.